Vicore Pharma Holding AB (OSTO:VICO) Net Margin %: -18,042.52% (As of Mar. 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
28 GF Score
Price kr12.12
! 3 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Net Margin %?

Vicore Pharma Holding AB OSTO:VICO +1.85% 28 Net Margin % is -18,042.52% as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Vicore Pharma Holding AB ranks worse than 94.08% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Vicore Pharma Holding AB's Net Income for the three months ended in Mar. 2026 was kr-108.62 Mil. Vicore Pharma Holding AB's Revenue for the three months ended in Mar. 2026 was kr0.60 Mil. Therefore, Vicore Pharma Holding AB's net margin for the quarter that ended in Mar. 2026 was -18,042.52%.

The historical rank and industry rank for Vicore Pharma Holding AB's Net Margin % or its related term are showing as below:

OSTO:VICO' s Net Margin % Range Over the Past 10 Years
Min: -13454.92   Med: -2599.89   Max: -154.22
Current: -13454.92


OSTO:VICO's Net Margin % is ranked worse than
94.08% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs OSTO:VICO: -13454.92

Vicore Pharma Holding AB  (OSTO:VICO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Vicore Pharma Holding AB Net Margin % Related Terms


Vicore Pharma Holding AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Net Margin % Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -154.22 -12,509.14

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,503.92 -6,607.27 -14,930.66 -32,721.48 -18,042.52

OSTO:VICO vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Net Margin % falls into.


OSTO:VICO
28GF Score
Vicore Pharma Holding AB OSTO:VICO
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Vicore Pharma Holding AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-477.474/3.817
=-12,509.14 %

Vicore Pharma Holding AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-108.616/0.602
=-18,042.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -18,042.52% mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Net Margin % of -18,042.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #890 out of 946 companies in the Biotechnology industry, placing it in the top 94.1%.
Is Vicore Pharma Holding AB's Net Margin % too high?
Vicore Pharma Holding AB's current Net Margin % is -18,042.52%. Based on the distribution chart, Vicore Pharma Holding AB ranks #890 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #890 out of 946 companies for Net Margin %. This places Vicore Pharma Holding AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Net Margin % is -18,042.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Net Margin % of -18,042.52%. The current Net Margin % is -18,042.52%. Vicore Pharma Holding AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Net Margin % is -18,042.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
28GF Score

Get the complete analysis for OSTO:VICO

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.12
Price